Russia Proposes Law to Criminalize Vape Sales to Minors

Nov.22.2024
Russia Proposes Law to Criminalize Vape Sales to Minors
The Russian State Duma plans to introduce a new bill prohibiting the sale of vapes to minors, making such actions subject to criminal liability.

According to a report by TASS on November 21st, Vyacheslav Volodin, the Chairman of the Russian State Duma, announced that a new bill is being prepared that will introduce criminal liability for selling e-cigarettes to minors. Additionally, fines for such illegal actions are also planned to be increased.


Wolokin pointed out that the existing regulatory measures are clearly not effective enough. Therefore, his colleagues have proposed holding individuals accountable for selling e-cigarettes to minors and also increasing the corresponding fines.


This is an important step in restoring order in the area. You and I need to continue working hard to address other issues related to protecting children's health. Of course, we must not allow the sale of alcohol, cigarettes, e-cigarettes, and many other prohibited products to minors.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

ITGA 与 2Firsts 签署战略合作备忘录,共同支持全球烟草种植者
ITGA 与 2Firsts 签署战略合作备忘录,共同支持全球烟草种植者
ITGA Annual General Meeting 2025 held in Germany alongside InterTabac/InterSupply 2025 showcases global tobacco supply chain opportunities.
Sep.23 by 2FIRSTS.ai
Product | Following the discontinuation of the AF5000, ELFBAR launches compliant alternative AF5500 in the UK.
Product | Following the discontinuation of the AF5000, ELFBAR launches compliant alternative AF5500 in the UK.
ELFBAR has launched the AF5500 in the UK, featuring a 12ml e-liquid capacity. Both its appearance and naming are similar to the popular "2+10" product, the AF5000, which was previously a bestseller in the region. The AF5000 has been removed from the market due to the disposable vape ban, and the AF5500 is likely to be its compliant alternative.
Sep.05 by 2FIRSTS.ai
Singapore's Crackdown on E-cigarettes May Benefit, Batam Island: Local Tourism Board Says It Could Become an Alternative Destination for Singaporeans
Singapore's Crackdown on E-cigarettes May Benefit, Batam Island: Local Tourism Board Says It Could Become an Alternative Destination for Singaporeans
The head of the tourism bureau of Indonesia's Batam Island said that Singapore's decision to crack down on e-cigarettes and treat them as a "drug issue" might boost cross-border travel, as Singaporeans may head to Batam, just an hour's ferry ride away. Batam Island has already benefited from Singapore's previous strict regulations.
Aug.29 by 2FIRSTS.ai
FDA Calls on Retailers to Remove Illegal E-Cigarettes from Shelves, Will Send List of Legal Products to 300,000 Stores
FDA Calls on Retailers to Remove Illegal E-Cigarettes from Shelves, Will Send List of Legal Products to 300,000 Stores
FDA launches national retail compliance initiative to combat illegal e-cigarette sales targeting youth, issuing guidance materials to over 300k retailers.
Oct.08 by 2FIRSTS.ai
Philip Morris International's five-year EU investment exceeds €43 billion, generating nearly €290 billion in economic impact
Philip Morris International's five-year EU investment exceeds €43 billion, generating nearly €290 billion in economic impact
According to Ernst & Young Parthenon research, Philip Morris International (PMI) invested over 43 billion euros in the EU from 2019 to 2023. It brought nearly 290 billion euros in economic impact, supported about 1 million jobs (21,500 direct hires in 2023), put 19.6 billion euros into over 45,000 suppliers, spent 625 million euros on tobacco leaf procurement, 2.3 billion euros on R&D, and exported over 33 billion euros to non-EU markets.
Sep.19 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai